Document:

Exhibit 10.20

 

PLACEMENT AGENCY AGREEMENT

 

March 19, 2015

 

Aegis Capital Corp.

810 Seventh Ave, 11th Floor

New York, NY 10019

 

		Re:	Matinas BioPharma Holdings, Inc. 

 

Ladies and Gentlemen:

 

This Placement Agency Agreement
("Agreement") sets forth the terms upon which Aegis Capital Corp., a New York corporation, and a registered broker-dealer
and member of the Financial Industry Regulatory Authority ("FINRA") (the “Placement Agent”),
shall be engaged by Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), to act as exclusive
Placement Agent in connection with the private placement (the “Offering”) of units (“Units”)
of securities of the Company, each Unit consisting of (i) 1 share of common stock, par value $0.0001 per share (the “Common
Stock”), of the Company (the “Shares”) and (ii) 1 warrant (the “Warrants”), with
each Warrant entitling the holder to purchase one share of Common Stock for a five-year period at an exercise price of $0.75 per
share. The Offering will consist of a minimum of 7,000,000 Units ($3,500,000) (the “Minimum Amount”) and a maximum
of 14,000,000 Units ($7,000,000) (the “Maximum Amount”). In the event the Offering is oversubscribed, the Company
and the Placement Agent may, in their mutual discretion, sell up to 6,000,000 additional Units for an additional aggregate purchase
price of $3,000,000 (the “Over-allotment”).

 

The purchase price for
the Units will be $0.50 per Unit (the “Offering Price”), with a minimum investment of $250,000; provided,
however, that subscriptions for lesser amounts may be accepted in the Company’s and Placement Agent’s
joint discretion. The Placement Agent shall accept subscriptions only from persons or entities who qualify as “accredited
investors,” as such term is defined in Rule 501 of Regulation D (“Regulation D”) as promulgated by the
United States Securities and Exchange Commission (the “Commission”) under Section 4(a)(2) of the Securities
Act of 1933, as amended (the “Act”). The Units will be offered until the earlier of (i) the termination
of the Offering as provided herein, (ii) the time that all Units offered in the Offering are sold or (iii) May 18, 2015 (“Initial
Offering Period”), which date may be extended by the Placement Agent and the Company in their joint discretion until
June 17, 2015 (this additional period and the Initial Offering Period shall be referred to as the “Offering Period”).
The date on which the Offering expires or is terminated shall be referred to as the “Termination Date.” 

 

With respect to the Offering,
the Company shall provide the Placement Agent, on terms set forth herein, the right to offer and sell all of the Units being offered.
Purchases of Units may be made by the Placement Agent and its officers, directors, employees and affiliates. All such purchases,
together with purchases by officers, directors, employees and affiliates of the Company, may be used to satisfy the Minimum Amount
if the Minimum Amount has not been subscribed for on or before the end of the Offering Period. It is understood that no sale shall
be regarded as effective unless and until accepted by the Company. The Company may, in its sole discretion, accept or reject, in
whole or in part, any prospective investment in the Units or allot to any prospective subscriber less than the number of Units
that such subscriber desires to purchase.

 

    	 

    	 

    

 

The Offering will be made
by the Company solely pursuant to the Memorandum (as defined below), which at all times will be in form and substance reasonably
acceptable to the Company, the Placement Agent and their respective counsel and contain such legends and other information as the
Company, the Placement Agent and their respective counsel, may, from time to time, deem necessary and desirable to be set forth
therein. “Memorandum” as used in this Agreement means the Company’s Confidential Private Placement Memorandum
dated on or about March ___, 2015, inclusive of all annexes, and all amendments, supplements and appendices thereto.

 

1.           Appointment
of Placement Agent. On the basis of the representations and warranties provided herein, and subject to the terms and conditions
set forth herein, the Placement Agent is appointed as exclusive Placement Agent for the Company during the Offering Period to assist
the Company in finding qualified subscribers for the Offering. Subject to the consent of Company, which will not be unreasonably
withheld, delayed or conditioned, the Placement Agent may sell Units through other broker-dealers who are FINRA members and may
reallow all or a portion of the Agent Compensation (as defined in Section 3(b) below) it receives to such other broker-dealers.
On the basis of such representations and warranties and subject to such terms and conditions, the Placement Agent hereby accepts
such appointment and agrees to perform its services hereunder diligently and in good faith and in a professional and businesslike
manner and to use its reasonable efforts to assist the Company in (A) finding subscribers of Units who qualify as “accredited
investors,” as such term is defined in Rule 501 of Regulation D, and (B) completing the Offering. The Placement Agent has
no obligation to purchase any of the Units. Unless sooner terminated in accordance with this Agreement, the engagement of the Placement
Agent hereunder shall continue until the later of the Termination Date or the Final Closing (as defined below).

 

2.           Representations,
Warranties and Covenants of the Company. The representations and warranties of the Company (as used in this Agreement, the
“Company” refers to Matinas BioPharma Holdings, Inc. and its subsidiaries) to the Placement Agent contained in this
Section 2 are true and correct as of the date of this Agreement.

 

(a)          The
Memorandum has been prepared by the Company, in conformity with all applicable laws, and is in compliance in all material respects
with Regulation D and Section 4(a)(2) of the Act and the requirements of all other rules and regulations (the “Regulations”)
of the Commission relating to offerings of the type contemplated by the Offering, and the applicable securities laws and the rules
and regulations of those jurisdictions wherein the Placement Agent notifies the Company that the Units are to be offered and sold
excluding any foreign jurisdictions. The Units will be offered and sold pursuant to the registration exemption provided by Regulation
D and Section 4(a)(2) of the Act as a transaction not involving a public offering and the requirements of any other applicable
state securities laws and the respective rules and regulations thereunder in those United States jurisdictions in which the Placement
Agent notifies the Company that the Units are being offered for sale. None of the Company, its affiliates, or any person acting
on its or their behalf (other than the Placement Agent, its affiliates or any person acting on its behalf, in respect of which
no representation is made) has taken nor will it take any action that conflicts with the conditions and requirements of, or that
would make unavailable with respect to the Offering, the exemption(s) from registration available pursuant to Rule 506 of Regulation
D or Section 4(a)(2) of the Act, or knows of any reason why any such exemption would be otherwise unavailable to it. None of the
Company, its predecessors or affiliates has been subject to any order, judgment or decree of any court of competent jurisdiction
temporarily, preliminarily or permanently enjoining such person for failing to comply with Rule 503 of Regulation D. The Company
has not, for a period of six months prior to the commencement of the offering of Units, sold, offered for sale or solicited any
offer to buy any of its securities in a manner that would be integrated with the offer and sale of the Units pursuant to this Agreement
and would cause the exemption from registration set forth in Rule 506 of Regulation D to become unavailable with respect to the
offer and sale of the Units pursuant to this Agreement in the United States.

 

    	2

    	 

    

 

(b)          The
Memorandum does not include any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading: provided,
however, the foregoing does not apply to any statements or omissions made solely in reliance on and in conformity with written
information furnished to the Company by the Company or the Placement Agent specifically for use in the preparation thereof. To
the knowledge of the Company, none of the statements, documents, certificates or other items made, prepared or supplied by the
Company with respect to the transactions contemplated hereby contains an untrue statement of a material fact or omits to state
a material fact necessary to make the statements contained therein not misleading in light of the circumstances in which they were
made. There is no fact which the Company has not disclosed in the Memorandum and of which the Company is aware that materially
adversely affects or that could reasonably be expected to have a material adverse effect on the (i) assets, liabilities, results
of operations, condition (financial or otherwise), business or business prospects of the Company or (ii) ability of the Company
to perform its obligations under this Agreement. Notwithstanding anything to the contrary herein, the Company makes no representation
or warranty with respect to any estimates, projections and other forecasts and plans (including the reasonableness of the assumptions
underlying such estimates, projections and other forecasts and plans) that may have been delivered to the Placement Agent or its
representatives or that are contained in the Memorandum, except that such estimates, projections and other forecasts and plans
have been prepared in good faith on the basis of assumptions stated therein, which assumptions were believed to be reasonable at
the time of such preparation.

 

    	3

    	 

    

 

(c)          The
Company and its “Subsidiaries” (which for purposes of this Agreement means Matinas BioPharma Inc. and Aquarius
Biotechnologies, Inc.), are entities duly organized and validly existing in good standing under the laws of the jurisdiction in
which they are formed, and have the requisite power and authority to own their properties and to carry on their business as now
being conducted.  Other than the Subsidiaries, the Company is not a party to any joint venture and does not directly or indirectly
own or hold capital stock or an equity or similar interest in any entity. Each of the Company and its Subsidiaries is duly qualified
as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature
of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or
be in good standing would not have a Material Adverse Effect.  As used in this Agreement, “Material Adverse Effect”
means any material adverse effect on the business, properties, assets, operations, results of operations, condition (financial
or otherwise) or prospects of the Company and its Subsidiaries, taken as a whole, or on the transactions contemplated hereby and
the other Transaction Documents (as defined below) or by the agreements and instruments to be entered into in connection herewith
or therewith, or on the authority or ability of the Company to perform its obligations under the Transaction Documents (as defined
below).   Except as set forth in the Memorandum or the Company Reports, the Company owns, directly or indirectly, all of the
capital stock or other equity interests of each Subsidiary free and clear of any liens (other than Permitted Encumbrances), and
all the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities. “Permitted Encumbrances”
shall means (a) mechanic’s, materialmen’s, and similar liens, securing payment of sums not yet due and payable
and for which an appropriate reserve has been established, (b) liens for taxes not yet delinquent or for taxes that the taxpayer
is contesting in good faith through appropriate proceedings and for which an appropriate reserve has been established in the financial
statements of such taxpayer, (c) purchase money liens and liens securing rental payments under capital lease arrangements,
and (d) other liens arising in the ordinary course of business and not incurred in connection with the borrowing of money.

 

(d)          The
Company has all requisite corporate power and authority to conduct its business as presently conducted and as proposed to be conducted
(as described in the Memorandum or the Company Reports), to enter into and perform its obligations under this Agreement, the Subscription
Agreement substantially in the form of Annex A to the Memorandum (the “Subscription Agreement”, the Registration
Rights Agreement substantially in the form of Annex B to the Memorandum (the “Registration Rights Agreement”),
and the other agreements contemplated hereby (this Agreement, the Subscription Agreement, the Registration Rights Agreement and
the other agreements contemplated hereby that the Company is executing and delivering hereunder are collectively referred to herein
as the “Transaction Documents”) and subject to necessary Board approvals, to issue, sell and deliver the Units,
the shares of Common Stock underlying the Units, and the shares of Common Stock issuable upon exercise of the Warrants (the “Warrant
Shares”), the Agent Warrants (as defined in Section 3(b)) and the Agent Warrant Shares (as defined in Section 3(b)).
Prior to the First Closing (as defined below in Section 4(e)), each of the Transaction Documents will have been duly authorized.
This Agreement has been duly authorized, executed and delivered and constitutes, and each of the other Transaction Documents, upon
due execution and delivery, will constitute, valid and binding obligations of the Company, enforceable against the Company in accordance
with their respective terms (i) except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium
or other similar laws now or hereafter in effect related to laws affecting creditors’ rights generally, including the effect
of statutory and other laws regarding fraudulent conveyances and preferential transfers, and except that no representation is made
herein regarding the enforceability of the Company’s obligations to provide indemnification and contribution remedies under
the securities laws and (ii) subject to the limitations imposed by general equitable principles (regardless of whether such enforceability
is considered in a proceeding at law or in equity).

 

    	4

    	 

    

 

(e)          As
of the date of the First Closing, Matinas BioPharma Holdings, Inc. will have the authorized and outstanding capital stock as set
forth under the heading “Capitalization” in the Memorandum. All outstanding shares of capital stock of Matinas BioPharma
Holdings, Inc. are duly authorized, validly issued and outstanding, fully paid and nonassessable. Except as described in the Memorandum
or the Company Reports, as of the date of the First Closing: (i) there will be no outstanding options, stock subscription agreements,
warrants or other rights permitting or requiring Matinas BioPharma Holdings, Inc. or others to purchase or acquire any shares of
capital stock or other equity securities of Matinas BioPharma Holdings, Inc. or to pay any dividend or make any other distribution
in respect thereof; (ii) there will be no securities issued or outstanding which are convertible into or exchangeable for any of
the foregoing and there are no contracts, commitments or understandings, whether or not in writing, to issue or grant any such
option, warrant, right or convertible or exchangeable security; (iii) no shares of stock or other securities of Matinas BioPharma
Holdings, Inc. are reserved for issuance for any purpose; (iv) there will be no voting trusts or other contracts, commitments,
understandings, arrangements or restrictions of any kind with respect to the ownership, voting or transfer of shares of stock or
other securities of Matinas BioPharma Holdings, Inc., including, without limitation, any preemptive rights, rights of first refusal,
proxies or similar rights, and (v) no person holds a right to require Matinas BioPharma Holdings, Inc. to register any of its securities
under the Act or to participate in any such registration. As of the date of the First Closing, the issued and outstanding shares
of capital stock of Matinas BioPharma Holdings, Inc. will conform in all material respects to all statements in relation thereto
contained in the Memorandum and the Memorandum describes all material terms and conditions thereof. All issuances by Matinas BioPharma
Holdings, Inc. of its securities have been, at the times of their issuance, either subject to an effective registration statement
under the Act or exempt from registration under the Act and any applicable state securities laws.

 

(f)          Immediately
prior to the First Closing, the shares of Common Stock underlying the Units, the Warrants, the Warrant Shares, the Agent Warrants
and the Agent Warrant Shares will have been duly authorized and, when issued and delivered against payment therefor as provided
in the Transaction Documents, will be validly issued, fully paid and nonassessable. No holder of any of the shares of Common Stock
underlying the Units, the Warrants, the Warrant Shares, the Agent Warrants or the Agent Warrant Shares will be subject to personal
liability solely by reason of being such a holder, and except as described in the Memorandum, none of the shares of Common Stock
underlying the Units, the Warrants, the Warrant Shares, the Agent Warrants or the Agent Warrant Shares are subject to preemptive
or similar rights of any stockholder or security holder of the Company or an adjustment under the antidilution or exercise rights
of any holders of any outstanding shares of capital stock, options, warrants or other rights to acquire any securities of the Company.
Immediately prior to the First Closing, a sufficient number of authorized but unissued shares of Common Stock will have been reserved
for issuance upon the exercise of the Warrants and the Agent Warrants.

 

    	5

    	 

    

 

(g)          None
of the execution and delivery of or performance by the Company under this Agreement or any of the other Transaction Documents or
the consummation of the transactions herein or therein contemplated conflicts with or violates, or will result in the creation
or imposition of, any lien, charge or other encumbrance upon any of the assets of the Company under any agreement or other instrument
to which the Company is a party or by which the Company or its assets may be bound, or any term of the certificate of incorporation
or by-laws of the Company, or any license, permit, judgment, decree, order, statute, rule or regulation applicable to the Company
or any of its assets, except in the case of a conflict, violation, lien, charge or other encumbrance (except with respect to the
Company’s Certificate of Incorporation or By-laws) which would not reasonably be expected to have a Material Adverse
Effect.

 

(h)          No
consent, authorization or filing of or with any court or governmental authority is required in connection with the issuance or
the consummation of the transactions contemplated herein or in the other Transaction Documents, except for required filings with
the Commission and the applicable state securities commissions relating specifically to the Offering (all of which filings will
be duly made by, or on behalf of, the Company), other than those which are required to be made after the First Closing (all of
which will be duly made on a timely basis).

 

(i)          The
Company Reports (as defined below) constitute all of the documents required to be filed by the Company with the Commission, including
under Section 13 or subsections (a) or (c) of Section 14 of the Securities Exchange Act of 1934 (the “Exchange Act”),
through the date of this Agreement. The Company Reports complied in all material respects with the requirements of the Exchange
Act and the rules and regulations thereunder as of their respective filing dates. As of the date hereof, there are no outstanding
or unresolved comments in comment letters received from the staff of the Commission with respect to any of the Company Reports.
As of their respective dates, the Company Reports did not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading. The “Company Reports” shall mean (a) the Company’s Special Financial Report on Form
10-K pursuant to Rule 15d-2 under the Exchange Act containing Financial Statements for the year ended December 31, 2013 and (b) all
other reports filed by the Company under Section 13 or subsections (a) or (c) of Section 14 of the Exchange Act with
the Commission since April 11, 2014 (such reports are collectively referred to herein as the “Company Reports”).

 

(j)          The
audited financial statements and unaudited interim financial statements of the Company included in the Company Reports and/or the
Memorandum (collectively, the “Company Financial Statements”), present fairly, in all material respects, the
financial position of the Company as of the dates specified and the results of operations for the periods covered thereby. Such
Financial Statements were prepared in accordance with United States generally accepted accounting principles applied on
a consistent basis throughout the periods indicated, except that the unaudited financial statements omit full notes, and except
for normal year end adjustments. Except as set forth in such Financial Statements or otherwise disclosed in the Memorandum or the
Company Reports, the Company has no known material liabilities of any kind, whether accrued, absolute or contingent, or otherwise,
and subsequent to the date of the Memorandum and prior to the date of the First Closing it shall not enter into any material transactions
or commitments without promptly thereafter notifying the Placement Agent in writing of any such material transaction or commitment.
The other financial and statistical information with respect to the Company and any pro forma information and related notes included
in the Memorandum present fairly in all material respects the information shown therein on a basis consistent with the Financial
Statements of the Company included in the Company Reports and/or the Memorandum. The Company does not know of any facts,
circumstances or conditions which could materially adversely affect its operations, earnings or prospects that have not been fully
disclosed in the Company Reports or the Memorandum.

 

    	6

    	 

    

 

(k)          Except
as disclosed in the Memorandum, since the date of the Company’ most recent financial statements contained in the Memorandum,
there has been no Material Adverse Effect. Except as disclosed in the Memorandum, since the date of the Company’s most recent
financial statements contained in the Memorandum, the Company has not (i) declared or paid any dividends, (ii) sold any assets,
individually or in the aggregate, in excess of $75,000 outside of the ordinary course of business or (iii) had capital expenditures,
individually or in the aggregate, in excess of $75,000. The Company has not taken any steps to seek protection pursuant to any
bankruptcy law nor does the Company have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy
proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so.

 

(l)          Except
as disclosed in the Memorandum or the Company Reports, the Company (i) has no outstanding Indebtedness (as defined below) in excess
of $75,000, (ii) is not a party to any contract, agreement or instrument, the violation of which, or default under which, by the
other party(ies) to such contract, agreement or instrument would result in a Material Adverse Effect, or (iii) is not in violation
of any term of or in default under any contract, agreement or instrument relating to any Indebtedness, except where such violations
and defaults would not result, individually or in the aggregate, in a Material Adverse Effect. For purposes of this Agreement:
(x) “Indebtedness” of any Person means without duplication, (A) all indebtedness for borrowed money, (B) all
obligations issued, undertaken or assumed as the deferred purchase price of property or services including (without limitation)
“Capital Leases” (as defined under GAAP) (other than trade payables entered into in the ordinary course of business),
(C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D)
all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection
with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other
title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds
of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are
limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which,
in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness
referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent
or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property
or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property
has not assumed or become liable for the payment of such indebtedness, and (H) except for obligations owed to service providers
of the Company in connection with this Offering, all Contingent Obligations (as defined below) in respect of indebtedness or obligations
of others of the kinds referred to in clauses (A) through (G) above of at least $75,000; (y) “Contingent Obligation”
means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness,
lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability,
or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged,
or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole
or in part) against loss with respect thereto; and (z) “Person” means an individual, a limited liability company,
a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency
thereof.

 

    	7

    	 

    

 

(m)          The
conduct of business by the Company as presently and proposed to be conducted is not subject to continuing oversight, supervision,
regulation or examination by any governmental official or body of the United States, or any other jurisdiction wherein the Company
conducts or proposes to conduct such business, except as described in the Memorandum or the Company Reports. The Company has obtained
all material licenses, permits and other governmental authorizations necessary to conduct its business as presently conducted.
The Company has not received any notice of any violation of, or noncompliance with, any federal, state, local or foreign laws,
ordinances, regulations and orders (including, without limitation, those relating to environmental protection, occupational safety
and health, securities laws, equal employment opportunity, consumer protection, credit reporting, “truth-in-lending”,
and warranties and trade practices) applicable to its business, the violation of, or noncompliance with, would have a Material
Adverse Effect, and the Company knows of no facts or set of circumstances which could give rise to such a notice.

 

(n)          No
default by the Company or, to the knowledge of the Company, any other party, exists in the due performance under any material agreement
to which the Company is a party or to which any of its assets is subject (collectively, the “Company Agreements”).
The Company Agreements disclosed in the Memorandum or the Company Reports are the only material agreements to which the Company
is bound or by which its assets are subject, are accurately described in the Memorandum or the Company Reports and are in full
force and effect in accordance with their respective terms, subject to any applicable bankruptcy, insolvency or other laws affecting
the rights of creditors generally and to general equitable principles and the availability of specific performance.

 

(o)          The
Company owns all right, title and interest in, or possesses adequate and enforceable rights to use, all patents, patent applications,
trademarks, service marks, copyrights, rights, licenses, franchises, trade secrets, confidential information, processes and formulations
necessary for the conduct of its business as now conducted (collectively, the “Intangibles”). To the knowledge
of the Company, the Company has not infringed upon the rights of others with respect to the Intangibles and, except as disclosed
in the Memorandum or the Company Reports, the Company has not received notice that it has or may have infringed or is infringing
upon the rights of others with respect to the Intangibles, or any written notice of conflict with the asserted rights of others
with respect to the Intangibles. To the knowledge of the Company, no others have infringed upon the rights of the Company with
respect to the Intangibles. Except as set forth in the Memorandum or the Company Reports, none of the Company’ Intangibles
have expired or terminated, or are expected to expire or terminate, within three years from the date of this Agreement.

 

    	8

    	 

    

 

(p)          The
Company is not a party to any collective bargaining agreement nor does it employ any member of a union. No executive officer of
the Company (as defined in Rule 501(f) of the Act) has notified the Company that such officer intends to leave the Company or otherwise
terminate such officer's employment with the Company. No executive officer of the Company, to the knowledge of the Company, is
in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each
such executive officer does not subject the Company to any liability with respect to any of the foregoing matters. The Company
is in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices
and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

(q)          Subsequent
to the respective dates as of which information is given in the Memorandum, the Company has operated its business in the ordinary
course and, except as may otherwise be set forth in the Memorandum or the Company Reports, there has been no: (i) Material Adverse
Effect; (ii) transaction otherwise than in the ordinary course of business consistent with past practice; (iii) issuance of any
securities (debt or equity) or any rights to acquire any such securities other than pursuant to equity incentive plans approved
by its Board of Directors; (iv) damage, loss or destruction, whether or not covered by insurance, with respect to any asset or
property of the Company; or (v) agreement to permit any of the foregoing.

 

(r)          Except
as set forth in the Memorandum or the Company Reports, there are no actions, suits, claims, hearings or proceedings pending before
any court or governmental authority or, to the knowledge of the Company, threatened, against the Company, or involving its assets
or any of its officers or directors (in their capacity as such) which, if determined adversely to the Company or such officer or
director, could reasonably be expected to have a Material Adverse Effect or adversely affect the transactions contemplated by this
Agreement or the Merger Agreement (as hereinafter defined) or the enforceability thereof.

 

(s)          The
Company is not: (i) in violation of its Certificate of Incorporation or By-laws; (ii) in default of any indenture, mortgage, deed
of trust, note or other agreement or instrument to which the Company is a party or by which it is or may be bound or to which any
of its assets may be subject, the default of which could reasonably be expected to have a Material Adverse Effect; (iii) in violation
of any statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect; or (iv)
in violation of any judgment, decree or order of any court or governmental body having jurisdiction over the Company and specifically
naming the Company, which violation or violations individually, or in the aggregate, could reasonably be expected to have a Material
Adverse Effect.

 

(t)          Except
as disclosed in the Memorandum or the Company Reports, as of the date of this Agreement, no current or former stockholder, director,
officer or employee of the Company, nor, to the knowledge of the Company, any affiliate of any such person is presently, directly
or indirectly through his affiliation with any other person or entity, a party to any loan from the Company or any other transaction
(other than as an employee) with the Company providing for the furnishing of services by, or rental of any personal property from,
or otherwise requiring cash payments to any such person.

 

    	9

    	 

    

 

(u)          Except
as disclosed in the Memorandum or the Company Reports, the Company has filed, on a timely basis, each federal, state, local and
foreign tax return, report and declarations that were required to be filed, or has requested an extension therefor and has paid
all taxes and all related assessments, charges, penalties and interest to the extent that the same have become due. There are no
unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
know of no basis for any such claim. The Company has not executed a waiver with respect to the statute of limitations relating
to the assessment or collection of any foreign, federal, state or local tax. To the Company’ knowledge, none of the Company’
tax returns is presently being audited by any taxing authority. No liens have been filed and no claims are being asserted by or
against the Company with respect to any taxes (other than liens for taxes not yet due and payable). The Company has not received
notice of assessment or proposed assessment of any taxes claimed to be owed by it or any other Person on its behalf. The Company
is not a party to any tax sharing or tax indemnity agreement or any other agreement of a similar nature that remains in effect.
The Company has complied in all material respects with all applicable legal requirements relating to the payment and withholding
of taxes and, within the time and in the manner prescribed by law, has withheld from wages, fees and other payments and paid over
to the proper governmental or regulatory authorities all amounts required.

 

(v)         Neither
the Company, nor any director, officer, agent, employee or other Person acting on behalf of the Company has, in the course of its
actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic
government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
payment to any foreign or domestic government official or employee.

 

(w)          The
Company is not obligated to pay, and has not obligated the Placement Agent to pay, a finder’s or origination fee in connection
with the Offering (other than to the Placement Agent), and hereby agrees to indemnify the Placement Agent from any such claim made
by any other person as more fully set forth in Section 8 hereof. The Company has not offered for sale or solicited offers to purchase
the Units except for negotiations with the Placement Agent.

 

(x)          Until
the earlier of (i) the Termination Date and (ii) the Final Closing (as hereinafter defined), the Company will not issue any press
release, grant any interview, or otherwise communicate with the media in any manner whatsoever with respect to the Offering without
the Placement Agent’s prior consent, which consent will not unreasonably be withheld, delayed or conditioned.

 

    	10

    	 

    

 

(y)          Neither
the sale of the Units by the Company nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended,
or any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended)
or any enabling legislation or executive order relating thereto. Without limiting the foregoing, the Company is not (a) a person
whose property or interests in property are blocked pursuant to Section 1 of Executive Order 13224 of September 23, 2001 Blocking
Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49079 (2001))
or (b) a person who engages in any dealings or transactions, or be otherwise associated, with any such person. The Company and
its Subsidiaries are in compliance, in all material respects, with the USA Patriot Act of 2001 (signed into law October 26, 2001).

 

(z)          The
Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions
are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization;
and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.

 

(aa)         None
of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating
in the Offering, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on
the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of sale of the securities in the Offering (each, a "Company Covered Person" and, together,
"Company Covered Persons") is subject to any of the "Bad Actor" disqualifications described in Rule
506(d)(1)(i) to (viii) under the Securities Act (a "Disqualification Event”). The Company has exercised reasonable
care to determine whether any Company Covered Person is subject to a Disqualification Event. The Company has complied, to the extent
applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Placement Agent a copy of any disclosures
provided thereunder.

 

(bb)         The
Company is not aware of any person (other than a Placement Agent Covered Person (as defined below)) that has been or will be paid
(directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any the Units.

 

(cc)         The
Company will promptly notify the Placement Agent in writing of (i) any Disqualification Event relating to any Company Covered Person
and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Company Covered Person.

 

    	11

    	 

    

 

(dd)         The
Company has established, maintains and evaluates “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e)
and 15d-15(e) under the Exchange Act), which (i) are designed to ensure that information required to be disclosed in the reports
that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within time periods specified
by the Commission’s rules and forms, and that such information is accumulated and communicated to the Company’s
management, including its principal executive officer and its principal financial officer, as appropriate to allow timely decisions
regarding required disclosure, (ii) have been evaluated for effectiveness as of the end of the last fiscal period covered
by the Company Reports; and (iii) as of the end of the last fiscal period covered by the Company Reports, such disclosure
controls and procedures are effective at the reasonable assurance level to perform the functions for which they were established.
There are no significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which could adversely affect the Company’s ability to record, process, summarize, and report financial data to management
and the Board of Directors of the Company. The Company is not aware of any fraud, whether or not material, that involves management
or other employees who have a role in the Company’s internal control over financial reporting; and since the date of the
most recent evaluation of such disclosure controls and procedures, there have been no significant changes in internal control over
financial reporting or in other factors that  have materially affected, or are reasonably likely to materially affect, the
Company’s internal control over financial reporting, including any corrective actions with regard to significant deficiencies
and material weaknesses.

 

(ee)         Subject
to the exemptions available to the Company as an “emerging growth company,” as
defined in the Jumpstart Our Business Startups Act of 2012, the Company, and to its knowledge, all of the Company’s
directors or officers, in their capacities as such, is in compliance in all material respects with all applicable effective provisions
of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the Commission. Subject to the phase-in rules available
to the Company as a newly public company, each of the principal executive officer
and the principal financial officer of the Company (or each former principal executive officer of the Company and each former principal
financial officer of the Company as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley
Act with respect to all reports, schedules, forms, statements and other documents required to be filed by it with the Commission.
For purposes of the preceding sentence, “principal executive officer” and “principal financial officer”
shall have the meanings given to such terms in the Sarbanes-Oxley Act.

 

(ff)         No
representation or warranty contained in Section 2 of this Agreement contains any untrue statement of a material fact or omits to
state a material fact necessary to make the statements herein not misleading in the context of such representations and warranties.

 

2A.         Representations,
Warranties and Covenants of Placement Agent. The Placement Agent hereby represents and warrants to the Company that the following
representations and warranties are true and correct as of the date of this Agreement:

 

(a)          The
Placement Agent is a corporation duly organized, validly existing and in good standing under the laws of the State of New York
and has all requisite corporate power and authority to enter into this Agreement and to carry out and perform its obligations under
the terms of this Agreement.

 

    	12

    	 

    

 

(b)          This
Agreement has been duly authorized, executed and delivered by the Placement Agent, and upon due execution and delivery by the Company,
this Agreement will be a valid and binding agreement of the Placement Agent enforceable against it in accordance with its terms,
except as may be limited by principles of public policy and, as to enforceability, subject to applicable bankruptcy, insolvency,
reorganization, moratorium and similar laws relating to or affecting creditor’s rights from time to time in effect and subject
to general equity principles.

 

(c)          The
Placement Agent is a member of FINRA and is registered as a broker-dealer under the Exchange Act, and under the securities acts
of each state into which it is making offers or sales of the Units. None of the Placement Agent or its affiliates, or any person
acting on behalf of the foregoing (other than the Company, its affiliates or any person acting on its behalf, in respect of which
no representation is made) has taken nor will it take any action that conflicts with the conditions and requirements of, or that
would make unavailable with respect to the Offering, the exemption(s) from registration available pursuant to Rule 506 of Regulation
D or Section 4(a)(2) of the Act, or knows of any reason why any such exemption would be otherwise unavailable to it.

 

(d)          The
Placement Agent represents that neither it, nor to its knowledge any of its directors, executive officers, general partners, managing
members or other officers participating in the Offering (each, a "Placement Agent Covered Person" and, together,
"Placement Agent Covered Persons"), is subject to any Disqualification Event, except for a Disqualification Event
(i) contemplated by Rule 506(d)(2) of the Securities Act and (ii) a description of which has been furnished in writing to the Company
prior to the date hereof.

 

(e)          The
Placement Agent represents that it is not aware of any person (other than any Placement Agent Covered Person) that has been or
will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Units. Placement
Agent will promptly notify the Company of any agreement entered into between such Placement Agent and such person in connection
with such sale.

 

(f)          The
Placement Agent will notify the Company promptly in writing of (i) any Disqualification Event relating to any Placement Agent Covered
Person not previously disclosed to the Company in accordance with Section 2A(d) of this Agreement and (ii) any event that would,
with the passage of time, become a Disqualification Event relating to any Placement Agent Covered Person.

 

(g)          As
to Placement Agent only, the Memorandum does not include any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading: provided, however, the foregoing does not apply to any statements or omissions made solely in reliance
on and in conformity with written information furnished to Placement Agent by the Company specifically for use in the preparation
thereof.

 

(h)          There
are no actions, suits, claims, hearings or proceedings pending before any court or governmental authority or, to the knowledge
of Placement Agent, threatened, against Placement Agent or involving its assets or to the knowledge of Placement Agent, any of
its officers or directors (in their capacity as such) which, if determined adversely to Placement Agent or such officer or director,
could reasonably be expected to adversely affect Placement Agent’s ability to perform its obligations hereunder.

 

    	13

    	 

    

 

3.           Placement
Agent Compensation.

 

(a)          In
connection with the Offering, the Company will pay at each Closing a cash fee (the “Agent Cash Fee”) to the
Placement Agent equal to 10% of the gross proceeds from the sale of the Units consummated at such Closing.

 

(b)          As
additional compensation at the Final Closing the Company will issue to the Placement Agent (or its designee(s)) for nominal consideration,
warrants (the “Agent Warrants;” the Agent Cash Fee and Agent Warrants are sometimes referred to herein collectively
as “Agent Compensation”) to purchase shares of Common Stock (the shares of Common Stock issuable upon exercise
of the Agent Warrants are hereinafter referred to as the “Agent Warrant Shares”). The Agent Warrants shall be
exercisable for that number of shares of Common Stock equaling 10% of the number of shares of Common Stock (i) included in the
aggregate number of Units sold at all of the Closings, at an exercise price of $0.50 per share and (ii) issuable upon exercise
of the Warrants included in all of such Units, at an exercise price of $0.75 per share (the “Agent Warrants”). The
Agent’s Warrants shall be exercisable until the date that is five (5) years after the Final Closing, shall contain immediate
cashless exercise provisions and shall not be callable by the Company.

 

(c)          At
each Closing, the Company will pay the Placement Agent a non-accountable expense allowance equal to 3% of the gross proceeds from
the sale of the Units consummated at such Closing (the “Agent Expense Allowance”). The Placement Agent will
not bear any of the Company’s legal, accounting, printing or other expenses in connection with any transaction contemplated
hereby. Notwithstanding the foregoing, the Agent Expense Allowance otherwise payable to the Placement Agent at the First Closing
shall be offset by the $15,000 the Company previously advanced to legal counsel for the Placement Agent.

 

(d)          In
the event the Company elects to redeem the Warrants pursuant to the provisions thereto, the Placement Agent will be engaged as
exclusive warrant solicitation agent a reasonable period of time prior to the time notice of redemption is delivered to holders
of Warrants. The engagement letter will provide for the payment to the Placement Agent of, inter alia, a cash fee of 5% of the
exercise price for each Warrant exercised by a Warrant holder that has been solicited by the Placement Agent following a redemption
notice.

 

4.           Subscription
and Closing Procedures.

 

(a)          The
Company shall cause to be delivered to the Placement Agent copies of the Memorandum and has consented, and hereby consents, to
the use of such copies for the purposes permitted by the Act and applicable securities laws and in accordance with the terms and
conditions of this Agreement, and hereby authorizes the Placement Agent and its agents and employees to use the Memorandum in connection
with the sale of the Units until the earlier of (i) the Termination Date or (ii) the Final Closing, and no person or entity is
or will be authorized to give any information or make any representations other than those contained in the Memorandum or to use
any offering materials other than those contained in the Memorandum in connection with the sale of the Units.

 

    	14

    	 

    

 

(b)          The
Company shall make available to the Placement Agent and its representatives such information as may be reasonably requested in
making a reasonable investigation of the Company and their respective affairs and shall provide access to such employees during
normal business hours as shall be reasonably requested by the Placement Agent.

 

(c)          Each
prospective purchaser will be required to complete and execute an original signature page for the Subscription Agreement (the “Subscription
Documents”), which will be forwarded or delivered to the Placement Agent at the Placement Agent’s offices at
the address set forth in Section 12 hereof, together with the subscriber’s wire transfer to the Escrow Agent (as defined
below) of the full amount of the purchase price for the number of Units desired to be purchased, subject to the Placement Agent’s
right to approve acceptance of a check by the Escrow Agent in lieu of a wire transfer.

 

(d)          All
funds for subscriptions received from the Offering by the Placement Agent, if any, will be promptly forwarded to the Escrow Agent
for deposit into a non-interest bearing escrow account (the “Escrow Account”) established for such purpose with
Signature Bank (the “Escrow Agent”). All such funds for subscriptions will be held in the Escrow Account pursuant
to the terms of an escrow agreement among the Company, the Placement Agent and the Escrow Agent. The Company will pay all reasonable
fees related to the establishment and maintenance of the Escrow Account. The Company will either accept or reject, for any or no
reason, the Subscription Documents in a timely fashion and at each Closing the Company will countersign the Subscription Documents
and provide duplicate copies of such documents to the Placement Agent for distribution to the subscribers. The Company, or the
Placement Agent on the Company’s behalf, will promptly return to subscribers incomplete, improperly completed, improperly
executed and rejected subscriptions and give written notice thereof to the Placement Agent upon such return.

 

(e)          If
subscriptions for at least the Minimum Amount have been accepted prior to the Termination Date, as to which the funds therefor
have been collected by the Escrow Agent and all of the conditions set forth elsewhere in this Agreement are fulfilled, a closing
shall be held promptly with respect to Units sold (the “First Closing”). Thereafter remaining Units will continue
to be offered and sold until the Termination Date and additional closings (each a “Closing”) (the date on which
a Closing occurs is sometimes referred to as a “Closing Date”) may from time to time be conducted at times mutually
agreed to between the Placement Agent and the Company with respect to additional Units sold, with the final closing (“Final
Closing”) to occur within 10 days after the earlier of the Termination Date and the date on which the all Units has been
fully subscribed for. Delivery of payment for the accepted subscriptions for Units from funds held in the Escrow Account will be
made at each Closing against delivery of the Shares and Warrants by the Company. Executed certificates for the Common Stock and
Warrants will be in such authorized denominations and, with respect to investors located by the Placement Agent, will be registered
in such names as the Placement Agent may request and will be made available to the Placement Agent for checking and packaging at
the Placement Agent’s office at each Closing or within ten (10) business days following a Closing. At the final Closing or
within ten (10) business days thereafter, the Agent Warrants will be issued in such quantities and names as the Placement Agent
may request.

 

    	15

    	 

    

 

(f)          If
Subscription Documents for the Minimum Amount have not been received and accepted by the Company on or before the Termination Date
for any reason, the Offering will be terminated, no Units will be sold, and the Escrow Agent will, at the request of the Placement
Agent, cause all monies received from subscribers for the Units to be promptly returned to such subscribers without interest, penalty,
expense or deduction.

 

5.           Further
Covenants. The Company hereby covenants and agrees that:

 

(a)          Except
upon prior written notice to the Placement Agent, the Company shall not, at any time prior to the Final Closing, knowingly take
any action which would cause any of the representations and warranties made by it in this Agreement not to be complete and correct
in all material respects on and as of each Closing Date with the same force and effect as if such representations and warranties
had been made on and as of each such date (except to the extent any representation or warranty relates to an earlier date).

 

(b)          If,
at any time prior to the Final Closing, any event shall occur that causes a Material Adverse Effect, as a result of which it becomes
necessary to amend or supplement the Memorandum so that the representations and warranties herein remain true and correct in all
material respects, or in case it shall be necessary to amend or supplement the Memorandum to comply with Regulation D or any other
applicable securities laws or regulations, the Company will promptly notify the Placement Agent and shall, at its sole cost, prepare
and furnish to the Placement Agent copies of appropriate amendments and/or supplements in such quantities as the Placement Agent
may reasonably request. The Company will not at any time before the Final Closing prepare or use any amendment or supplement to
the Memorandum of which the Placement Agent will not previously have been advised and furnished with a copy, or which is not in
compliance in all material respects with the Act and other applicable securities laws. As soon as the Company is advised thereof,
the Company will advise the Placement Agent and its counsel, and confirm the advice in writing, of any order preventing or suspending
the use of the Memorandum, or the suspension of any exemption for such qualification or registration thereof for offering in any
jurisdiction, or of the institution or threatened institution of any proceedings for any of such purposes, and the Company will
use their reasonable best efforts to prevent the issuance of any such order and, if issued, to obtain as soon as reasonably possible
the lifting thereof.

 

(c)          The
Company shall comply with the Act, the Exchange Act and the rules and regulations thereunder, all applicable state securities laws
and the rules and regulations thereunder in the states in which the Company’s counsel has advised the Placement Agent and
the Company that the Units are qualified or registered for sale or exempt from such qualification or registration, so as to permit
the continuance of the sales of the Units, and will file or cause to be filed with the Commission, and shall promptly thereafter
forward or cause to be forwarded to the Placement Agent, any and all reports on Form D as are required.

 

    	16

    	 

    

 

(d)          The
Company shall use best efforts to qualify the Units for sale under the securities laws of such jurisdictions in the United States
as may be mutually agreed to by the Company and the Placement Agent, and the Company will make or cause to be made such applications
and furnish information as may be required for such purposes, provided that the Company will not be required to qualify as a foreign
corporation in any jurisdiction or execute a general consent to service of process. The Company will, from time to time, prepare
and file such statements and reports as are or may be required to continue such qualifications in effect for so long a period as
the Placement Agent may reasonably request with respect to the Offering.

 

(e)          The
Company shall place a legend on the certificates representing the Shares, Warrants and the Agent Warrants that the securities evidenced
thereby have not been registered under the Act or applicable state securities laws, setting forth or referring to the applicable
restrictions on transferability and sale of such securities under the Act and applicable state laws.

 

(f)          The
Company shall apply the net proceeds from the sale of the Units for the purposes substantially as described under the “Use
of Proceeds” section of the Memorandum. Except as set forth in the Memorandum, the Company shall not use any of the net proceeds
of the Offering to repay indebtedness to officers (other than accrued salaries incurred in the ordinary course of business), directors
or stockholders of the Company without the prior written consent of the Placement Agent.

 

(g)          During
the Offering Period, the Company shall afford each prospective purchaser of Units the opportunity to ask questions of and receive
answers from an officer of the Company concerning the terms and conditions of the Offering and the opportunity to obtain such other
additional information necessary to verify the accuracy of the Memorandum to the extent the Company possesses such information
or can acquire it without unreasonable expense.

 

(h)          Except
with the prior written consent of the Placement Agent, the Company shall not, at any time prior to the earlier of the Final Closing
or the Termination Date, except as contemplated by the Memorandum (i) engage in or commit to engage in any transaction outside
the ordinary course of business as described in the Memorandum, (ii) issue, agree to issue or set aside for issuance any securities
(debt or equity) or any rights to acquire any such securities, (iii) incur, outside the ordinary course of business, any material
indebtedness, (iv) dispose of any material assets, (v) make any material acquisition or (vi) change its business or operations.

 

(i)          The
Company shall pay all reasonable expenses incurred in connection with the preparation and printing of all necessary offering documents
and instruments related to the Offering and the issuance of the Shares, the Warrants and the Agent Warrants and will also pay the
Company's own expenses for accounting fees, legal fees and other costs involved with the Offering. The Company will provide at
its own expense such quantities of the Memorandum and other documents and instruments relating to the Offering as the Placement
Agent may reasonably request. All Blue Sky filings shall be prepared by the Company’s counsel at the Company’s
expense. Further, as promptly as practicable after the Final Closing, the Company shall prepare, at its own expense, velobound
"closing binders" relating to the Offering and will distribute one such binder to each of the Placement Agent and its
counsel.

 

    	17

    	 

    

 

(j)          Until
the earlier of the Termination Date or the Final Closing, neither the Company nor any person or entity acting on such persons’
behalf will negotiate with any other placement agent or underwriter with respect to a private or public offering of such entity’s
debt or equity securities. Neither the Company nor any person or entity acting on such persons’ behalf will, until the earlier
of the Termination Date or the Final Closing, without the prior written consent of the Placement Agent, offer for sale to, or solicit
offers to subscribe for Units from, or otherwise approach or negotiate in respect thereof with, any other person.

 

6.           Conditions
of Placement Agent’s Obligations. The obligations of the Placement Agent hereunder to effect a Closing are subject to
the fulfillment, at or before each Closing, of the following additional conditions:

 

(a)          Each
of the representations and warranties made by the Company qualified as to materiality shall be true and correct at all times prior
to and on each Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in
which case such representation or warranty shall be true and correct as of such earlier date, and the representations and warranties
made by the Company not qualified as to materiality shall be true and correct in all material respects at all times prior to and
on each Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which
case such representation or warranty shall be true and correct in all material respects as of such earlier date.

 

(b)          The
Company shall have performed and complied in all material respects with all agreements, covenants and conditions required to be
performed and complied with by it at or before the Closing.

 

(c)          The
Memorandum did not, and as of the date of any amendment or supplement thereto will not, include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading.

 

(d)          No
order suspending the use of the Memorandum or enjoining the Offering or sale of the Units shall have been issued, and no proceedings
for that purpose or a similar purpose shall have been initiated or pending, or, to the best of the Company’s knowledge, be
contemplated or threatened.

 

(e)          The
Placement Agent shall have received a certificate of the Chief Executive Officer of the Company, dated as of the Closing Date,
certifying as to the fulfillment of the conditions set forth in subparagraphs (a), (b), (c) and (d) above.

 

(f)          The
Company shall have delivered to the Placement Agent: (i) a certified charter document and good standing certificate of each of
the Company and each of its Subsidiaries, each dated as of a date within 10 days prior to the Closing Date from the secretary of
state of its jurisdiction of incorporation; and (ii) resolutions of the Company's Board of Directors approving this Agreement and
the transactions and agreements contemplated by this Agreement and the Memorandum, certified by the Chief Executive Officer of
the Company.

 

    	18

    	 

    

 

(g)          At
each Closing, the Company shall pay and/or issue to the Placement Agent the Agent Compensation and Agent Expense Allowance earned
in such Closing.

 

(h)          The
Company shall deliver to the Placement Agent a signed opinion of Lowenstein Sandler LLP, counsel to the Company, as of each
Closing Date, in form and substance reasonably satisfactory to the Placement Agent.

 

(i)          All
proceedings taken at or prior to the Closing in connection with the authorization, issuance and sale of the Shares, the Warrants
and the Agent Warrants will be reasonably satisfactory in form and substance to the Placement Agent and its counsel, and such counsel
shall have been furnished with all such documents, certificates and opinions as it may reasonably request upon reasonable prior
notice in connection with the transactions contemplated hereby.

 

7.          Conditions
of the Company’s Obligations. The obligations of the Company to effect a Closing are subject to the fulfillment,
at or before each Closing, of the condition that each of the representations and warranties made by Placement Agent herein are
true and correct as of each Closing Date.

 

8.           Indemnification.

 

(a)          The
Company will: (i) indemnify and hold harmless the Placement Agent, its agents and their respective officers, directors, employees,
selected dealers and each person, if any, who controls the Placement Agent within the meaning of the Section 15 of the Act or Section
20(a) of the Exchange Act and such selected dealers (each an “Indemnitee” or a "Placement Agent Party")
against, and pay or reimburse each Indemnitee for, any and all losses, claims, damages, liabilities or expenses whatsoever (or
actions or proceedings or investigations in respect thereof), joint or several (which will, for all purposes of this Agreement,
include, but not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees, including
appeals), to which any Indemnitee may become subject (x) under the Act or otherwise, in connection with the offer and sale of the
Units and (y) as a result of the breach of any representation, warranty or covenant made by the Company herein, regardless of whether
such losses, claims, damages, liabilities or expenses shall result from any claim by any Indemnitee or by any third party; and
(ii) reimburse each Indemnitee for any legal or other expenses reasonably incurred in connection with investigating or defending
against any such loss, claim, action, proceeding or investigation; provided, however, that the Company
will not be liable in any such case to the extent that any such claim, damage or liability is finally judicially determined to
have resulted exclusively from (A) an untrue statement or alleged untrue statement of a material fact made in the Memorandum, or
an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, made solely in reliance upon and in conformity with written information furnished to the Company by the
Placement Agent specifically for use in the Memorandum or (B) any violations by the Placement Agent of the Act or state securities
laws which does not result from a violation thereof by the Company, or any of its affiliates. In addition to the foregoing agreement
to indemnify and reimburse, the Company will indemnify and hold harmless each Indemnitee against any and all losses, claims, damages,
liabilities or expenses whatsoever (or actions or proceedings or investigations in respect thereof), joint or several (which shall,
for all purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable
attorneys' fees, including appeals) to which any Indemnitee may become subject insofar as such costs, expenses, losses, claims,
damages or liabilities arise out of or are based upon the claim of any person or entity that he or it is entitled to broker’s
or finder’s fees from any Indemnitee in connection with the Offering, other than fees due to the Placement Agent. The foregoing
indemnity agreements will be in addition to any liability the Company may otherwise have.

 

    	19

    	 

    

 

(b)          The
Placement Agent will indemnify and hold harmless the Company, its officers, directors, and each person, if any, who controls such
entity Section 15 of the Act or Section 20(a) of the Exchange Act against, and pay or reimburse any such person for, any and all
losses, claims, damages, liabilities or expenses whatsoever (or actions, proceedings or investigations in respect thereof) to which
the Company or any such person may become subject under the Act or otherwise, whether such losses, claims, damages, liabilities
or expenses shall result from any claim of the Company or any such person who controls the Company within the meaning of the Act
or by any third party, but only to the extent that such losses, claims, damages or liabilities are based upon (i) any untrue statement
or alleged untrue statement of any material fact contained in the Memorandum made in reliance upon and in conformity with information
contained in the Memorandum relating to the Placement Agent, or an omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, in either case, if made or omitted in
reliance upon and in conformity with written information furnished to the Company by the Placement Agent, specifically for use
in the preparation thereof or (ii) any violations by the Placement Agent of the Act or state securities laws which does not result
from a violation thereof by the Company, or any of its affiliates. The Placement Agent will reimburse the Company or any such person
for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim,
damage, liability or action, proceeding or investigation to which such indemnity obligation applies. The foregoing indemnity agreements
are in addition to any liability which the Placement Agent may otherwise have. Notwithstanding the foregoing, in no event (except
in the event of gross negligence or willful misconduct by the Placement Agent and only to the extent found in a final judgment
by a court of competent jurisdiction) shall the Placement Agent’s indemnification obligation hereunder exceed the amount
of the Agent’s Cash Fee actually received by it.

 

    	20

    	 

    

 

(c)          Promptly
after receipt by an indemnified party under this Section 8 of notice of the commencement of any action, claim, proceeding or investigation
(the “Action”), such indemnified party, if a claim in respect thereof is to be made against the indemnifying
party under this Section 8, will notify the indemnifying party of the commencement thereof, but the omission to so notify the indemnifying
party will not relieve it from any liability that it may have to any indemnified party under this Section 8 unless the indemnifying
party has been substantially prejudiced by such omission. The indemnifying party will be entitled to participate in and, to the
extent that it may wish, jointly with any other indemnifying party, to assume the defense thereof subject to the provisions herein
stated, with counsel reasonably satisfactory to such indemnified party. The indemnified party will have the right to employ separate
counsel in any such Action and to participate in the defense thereof, but the fees and expenses of such counsel will not be at
the expense of the indemnifying party if the indemnifying party has assumed the defense of the Action with counsel reasonably satisfactory
to the indemnified party, provided, however, that if the indemnified party shall be requested by the indemnifying
party to participate in the defense thereof or shall have concluded in good faith and specifically notified the indemnifying party
either that there may be specific defenses available to it that are different from or additional to those available to the indemnifying
party or that such Action involves or could have a material adverse effect upon it with respect to matters beyond the scope of
the indemnity agreements contained in this Agreement, then the counsel representing it, to the extent made necessary by such defenses,
shall have the right to direct such defenses of such Action on its behalf and in such case the reasonable fees and expenses of
such counsel in connection with any such participation or defenses shall be paid by the indemnifying party. No settlement of any
Action against an indemnified party will be made without the consent of the indemnifying party and the indemnified party, which
consent shall not be unreasonably withheld, delayed or conditioned in light of all factors of importance to such party, and no
indemnifying party shall be liable to indemnify any person for any settlement of any such claim effected without such indemnifying
party’s consent.

 

9.           Contribution.
To provide for just and equitable contribution, if: (i) an indemnified party makes a claim for indemnification pursuant to Section
8 hereof and it is finally determined, by a judgment, order or decree not subject to further appeal that such claims for indemnification
may not be enforced, even though this Agreement expressly provides for indemnification in such case; or (ii) any indemnified or
indemnifying party seeks contribution under the Act, the Exchange Act, or otherwise, then each indemnifying party shall contribute
to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative
benefits but also the relative fault of the Company on the one hand and the Placement Agent on the other in connection with the
statements or omissions which resulted in such losses, claims, damages, liabilities or expenses (or actions in respect thereof),
as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Placement
Agent on the other shall be deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses)
received by the Company bear to the total Agent Cash Fees received by the Placement Agent. The relative fault, in the case of an
untrue statement, alleged untrue statement, omission or alleged omission will be determined by, among other things, whether such
statement, alleged statement, omission or alleged omission relates to information supplied by the Company or by the Placement Agent,
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement,
alleged statement, omission or alleged omission. The Company and the Placement Agent agree that it would be unjust and inequitable
if the respective obligations of the Company and the Placement Agent for contribution were determined by pro rata
allocation of the aggregate losses, liabilities, claims, damages and expenses or by any other method or allocation that does not
reflect the equitable considerations referred to in this Section 9. No person guilty of a fraudulent misrepresentation (within
the meaning of Section 10(f) of the Act) will be entitled to contribution from any person who is not guilty of such fraudulent
misrepresentation. For purposes of this Section 9, each person, if any, who controls the Placement Agent within the meaning of
the Act will have the same rights to contribution as the Placement Agent, and each person, if any, who controls the Company within
the meaning of the Act will have the same rights to contribution as the Company, subject in each case to the provisions of this
Section 9. Anything in this Section 9 to the contrary notwithstanding, no party will be liable for contribution with respect to
the settlement of any claim or action effected without its written consent. This Section 9 is intended to supersede, to the extent
permitted by law, any right to contribution under the Act, the Exchange Act or otherwise available.

 

    	21

    	 

    

 

10.         Termination.

 

(a)          The
Offering may be terminated by the Placement Agent at any time prior to the expiration of the Offering Period in the event that:
(i) any of the representations, warranties or covenants of the Company contained herein or in the Memorandum shall prove to have
been false or misleading in any material respect when actually made; (ii) the Company shall have failed to perform any of its material
obligations hereunder or under any other Transaction Document or any other transaction document; (iii) there shall occur any event,
within the control of the Company that could materially adversely affect the transactions contemplated hereunder or the ability
of the Company to perform hereunder; or (iv) the Placement Agent determines that it is reasonably likely that any of the conditions
to Closing set forth herein will not, or cannot, be satisfied. In the event of a termination by the Placement Agent under Section
10(a)(iv), the Placement Agent shall not be entitled to any further compensation pursuant to these termination provisions.

 

(b)          This
Offering may be terminated by the Company at any time prior to the expiration of the Offering Period (i) in the event that the
Placement Agent shall have failed to perform any of its material obligations hereunder or (ii) on account of the Placement Agent’s
fraud, illegal or willful misconduct or gross negligence. In the event of any such termination pursuant to this Section 10(b),
the Placement Agent shall not be entitled to any further compensation pursuant to these termination provisions.

 

(c)          [Intentionally
omitted]

 

(d)          This
Offering may be terminated upon mutual agreement of the Company and the Placement Agent at any time prior to the expiration of
the Offering Period. In addition, upon the expiration of the Offering Period, the Offering shall terminate without any further
action of the parties hereto. If the Offering is terminated pursuant to this Section 10(d), then in cases in which no Closing had
been theretofore consummated, each party shall pay its own respective expenses.

 

(e)          Before
any termination by the Placement Agent under Section 10(a) or by the Company under Section 10(b) shall become effective, the terminating
party shall give written notice to the other party of its intention to terminate the Offering (the “Termination Notice”).
The Termination Notice shall specify the grounds for the proposed termination. If the specified grounds for termination, or their
resulting adverse effect on the transactions contemplated hereby, are curable, then the other party shall have ten (10) days from
the Termination Notice within which to remove such grounds or to eliminate all of their material adverse effects on the transactions
contemplated hereby; otherwise, the Offering shall terminate.

 

    	22

    	 

    

 

(f)          Upon
any termination pursuant to this Section 10, the Placement Agent and the Company will instruct Escrow Agent to cause all monies
received with respect to the subscriptions for Units not accepted by the Company to be promptly returned to such subscribers without
interest, penalty or deduction.

 

11.         Survival.

 

(a)          The
obligations of the parties to pay any costs and expenses hereunder and to provide indemnification and contribution as provided
herein shall survive any termination hereunder. In addition, the provisions of Sections 8 through 16 shall survive the sale of
the Units or any termination of the Offering hereunder.

 

(b)          The
respective indemnities, covenants, representations, warranties and other statements of the Company and the Placement Agent set
forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on
behalf of, and regardless of any access to information by, the Company or the Placement Agent, or any of their officers or directors
or any controlling person thereof, and will survive the sale of the Units or any termination of the Offering hereunder for a period
of four years from the earlier to occur of the Final Closing or the termination of the Offering.

 

12.         Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given
or made as of the date delivered personally, or the date mailed if mailed by registered or certified mail (postage prepaid, return
receipt requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like
changes of address which shall be effective upon receipt) or sent by facsimile transmission, with confirmation received, if sent
to the Placement Agent, will be mailed, delivered or telefaxed and confirmed to Aegis Capital Corp., 810 Seventh Ave, 11th Floor,
New York, New York 10019, Attention: Adam K. Stern, telefax number (646) 390-9122, with a copy (which shall not constitute notice)
to: Meister Seelig & Fein LLP, 125 Park Avenue, 7th Floor, New York, NY 10017, Attn: Kenneth S. Goodwin, Esq., telefax
number (646) 539-3663, if sent to the Company, will be mailed, delivered or telefaxed and confirmed to Matinas BioPharma Holdings,
Inc., 1545 Route 206 South, Suite 302, Bedminster, NJ 07921, Attn: Roelof Rongen, President & CEO, with a copy (which shall
not constitute notice) to: Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, NY 10020, Attn: Steven M. Skolnick, Esq.,
telefax number (973) 597 2477.

 

    	23

    	 

    

 

13.         Governing
Law, Jurisdiction. This Agreement shall be deemed to have been made and delivered in New York City and shall be governed as
to validity, interpretation, construction, affect and in all other respects by the internal laws of the State of New York. THE
PARTIES AGREE THAT ANY DISPUTE, CLAIM OR CONTROVERSY DIRECTLY OR INDIRECTLY RELATING TO OR ARISING OUT OF THIS AGREEMENT,
THE TERMINATION OR VALIDITY HEREOF, ANY ALLEGED BREACH OF THIS AGREEMENT OR THE ENGAGEMENT CONTEMPLATED HEREBY (ANY OF THE FOREGOING,
A “CLAIM”) SHALL BE SUBMITTED TO THE JUDICIAL ARBITRATION AND MEDIATION SERVICES, INC (“JAMS”), OR ITS
SUCCESSOR, IN NEW YORK, FOR FINAL AND BINDING ARBITRATION IN FRONT OF A PANEL OF THREE ARBITRATORS WITH JAMS IN NEW YORK, NEW YORK
UNDER THE JAMS COMPREHENSIVE ARBITRATION RULES AND PROCEDURES (WITH EACH OF THE SELLING AGENT AND THE COMPANY CHOOSING ONE ARBITRATOR,
AND THE CHOSEN ARBITRATORS CHOOSING THE THIRD ARBITRATOR).  THE ARBITRATORS SHALL, IN THEIR AWARD, ALLOCATE ALL OF THE COSTS
OF THE ARBITRATION, INCLUDING THE FEES OF THE ARBITRATORS AND THE REASONABLE ATTORNEYS’ FEES OF THE PREVAILING PARTY, AGAINST
THE PARTY WHO DID NOT PREVAIL.  THE AWARD IN THE ARBITRATION SHALL BE FINAL AND BINDING.  THE ARBITRATION SHALL BE GOVERNED
BY THE FEDERAL ARBITRATION ACT, 9 U.S.C. SEC. 1-16, AND THE JUDGMENT UPON THE AWARD RENDERED BY THE ARBITRATORS MAY BE ENTERED
BY ANY COURT HAVING JURISDICTION THEREOF.  THE COMPANY AND THE PLACEMENT AGENT AGREE AND CONSENT TO PERSONAL JURISDICTION,
SERVICE OF PROCESS AND VENUE IN ANY FEDERAL OR STATE COURT WITHIN THE STATE AND COUNTY OF NEW YORK IN CONNECTION WITH ANY ACTION
BROUGHT TO ENFORCE AN AWARD IN ARBITRATION.

 

14.         Miscellaneous.
No provision of this Agreement may be changed or terminated except by a writing signed by the party or parties to be charged therewith.
Unless expressly so provided, no party to this Agreement will be liable for the performance of any other party’s obligations
hereunder. Either party hereto may waive compliance by the other with any of the terms, provisions and conditions set forth herein;
provided, however, that any such waiver shall be in writing specifically setting forth those provisions waived thereby. No such
waiver shall be deemed to constitute or imply waiver of any other term, provision or condition of this Agreement. Neither party
may assign its rights or obligations under this Agreement to any other person or entity without the prior written consent of the
other party.

 

    	24

    	 

    

 

15.         Entire
Agreement; Severability. This Agreement together with any other agreement referred to herein supersedes all prior understandings
and written or oral agreements between the parties with respect to the Offering and the subject matter hereof. If any portion of
this Agreement shall be held invalid or unenforceable, then so far as is reasonable and possible (i) the remainder of this Agreement
shall be considered valid and enforceable and (ii) effect shall be given to the intent manifested by the portion held invalid or
unenforceable.

 

16.         Counterparts.
This Agreement may be executed in multiple counterparts, each of which may be executed by less than all of the parties and shall
be deemed to be an original instrument which shall be enforceable against the parties actually executing such counterparts and
all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement and of signature pages
by facsimile transmission shall constitute effective execution and delivery of this Agreement as to the parties and may be used
in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile shall be deemed to be their
original signatures for all purposes.

 

[Signatures on following page.]

 

    	25

    	 

    

 

If the foregoing is in
accordance with your understanding of the agreement among the Company and the Placement Agent, kindly sign and return this Agreement,
whereupon it will become a binding agreement between the Company and the Placement Agent in accordance with its terms.

 

	 	MATINAS BIOPHARMA HOLDINGS, INC.
	 	 	 
	 	By: 	/s/ Roelof Rongen
	 	Name:	Roelof Rongen
	 	Title:	President and Chief Executive Officer

 

Accepted and agreed to this

19th day of March, 2015:

 

AEGIS CAPITAL CORP. 

 

	By: 	/s/ Adam Stern	 
	Name:	Adam Stern	 
	Title: Head of Private Equity Banking	 

 

    	26Exhibit 10.21

 

SUBSCRIPTION AGREEMENT

 

Matinas BioPharma Holdings, Inc.

1545 Route 206 South, Suite 302

Bedminster, New Jersey

Ladies and Gentlemen:

 

1.          Subscription.
The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from Matinas
BioPharma Holdings, Inc., a Delaware corporation (the “Company”), the number of units (the “Units”) set
forth on the signature page hereof at a purchase price of $0.50 per Unit, with a minimum investment of $250,000 (500,000 Units)
(“Minimum Investment Amount”), or such lesser amount agreed to by the Company and the Placement Agent (as defined below).
Each Unit consists of (i) one share of common stock, par value $0.0001 per share (the “Common Stock”), of the Company
and (ii) one warrant (the “Warrants”), with each Warrant entitling the holder to purchase one share of Common Stock
for a five-year period commencing at the First Closing (as defined below) at an exercise price of $0.75 per share. The Units are
being sold in the Offering (as defined below), the initial closing of which may be scheduled at any time after subscriptions have
been received and accepted for at least the Minimum Offering Amount (as defined below) and other conditions to closing have been
satisfied. Thereafter, remaining Units will continue to be offered and sold until the date on which the Offering (as defined below)
expires, and additional closings (each a “Closing”) may from time to time be conducted at times mutually agreed to
between the Placement Agent (as defined below) and the Company with respect to those additional units sold.

 

2.          The
Offering. This subscription is submitted to you in accordance with and subject to the terms and conditions described in this
Subscription Agreement and the Confidential Private Placement Memorandum of the Company dated March 19, 2015, as amended or supplemented
from time to time, including all attachments, schedules and exhibits thereto (the “Memorandum”), relating to the offering
(the “Offering”) by the Company of a minimum of 7,000,000 Units ($3,500,000) (“Minimum Offering Amount”),
and up to a maximum of 14,000,000 Units ($7,000,000) (“Maximum Offering Amount”). In the event the Maximum Offering
Amount is sold, the Placement Agent (as defined below) and the Company shall have the right to place an additional 6,000,000 Units
($3,000,000) to cover over-allotments. Aegis Capital Corp. has been engaged as placement agent in connection with the Offering
(the “Placement Agent”). The terms of the Offering are more completely described in the Memorandum and such terms are
incorporated herein in their entirety.

 

    	 

    	 	 	 

    

 

3.          Payment.
The Purchaser will immediately make a wire transfer payment to, “Signature Bank, 261 Madison Ave., New York, NY 10016, ABA
No. 026013576 for credit to Matinas BioPharma Holdings, Inc., Signature Bank, as Escrow Agent, Account No. 1502471380” in
the full amount of the purchase price of the Units being subscribed for in the Offering. Wire transfer instructions are set forth
on page 12 hereof under the heading “To subscribe for Units in the private offering of Matinas BioPharma Holdings, Inc.”
Notwithstanding the foregoing, Placement Agent may approve acceptance of a check by the Escrow Agent in lieu of a wire transfer.
Upon approval of Placement Agent, Purchaser will immediately send a check payable to the order of “Matinas BioPharma Holdings,
Inc., Signature Bank, as Escrow Agent,” with the name and address of the Purchaser. Such funds will be held for the Purchaser's
benefit, and will be returned promptly, without interest or offset if this Subscription Agreement is not accepted by the Company,
the Offering is terminated pursuant to its terms by the Company prior to the First Closing (as hereinafter defined), or the Minimum
Offering Amount is not sold. Together with a wire transfer (or, pursuant to the Placement Agent’s approval of acceptance
of a check by the Escrow Agent in lieu of a wire transfer, a check) for the full purchase price, the Purchaser is delivering a
completed and executed Omnibus Signature Page to this Subscription Agreement and the Registration Rights Agreement, in the form
of [Exhibit B] to the Memorandum (the “Registration Rights Agreement”).

 

4.          Deposit
of Funds. All payments made as provided in Section 3 hereof shall be promptly forwarded by the Company or the Placement Agent,
as soon as practicable after receipt thereof, to Signature Bank (the “Escrow Agent”) for deposit into a non-interest-bearing
escrow account (the “Escrow Account”) until the earliest to occur of (a) the closing of the sale of the Minimum Offering
Amount (the “First Closing”) or the additional Closings that may be conducted from time to time, as applicable, (b)
the rejection of such subscription, and (c) the termination of the Offering by the Company or the Placement Agent. The Company
and the Placement Agent may continue to offer and sell the Units and conduct additional closings for the sale of additional Units
after the First Closing and until the termination of the Offering.

 

5.          Acceptance
of Subscription. The Purchaser understands and agrees that the Company, in their sole discretion, reserve the right to accept
or reject this or any other subscription for Units, in whole or in part, notwithstanding prior receipt by the Purchaser of notice
of acceptance of this subscription. The Company shall have no obligation hereunder until the Company shall execute and deliver
to the Purchaser an executed copy of this Subscription Agreement. If this subscription is rejected in whole, the Offering of Units
is terminated or the Minimum Offering Amount is not raised, all funds received from the Purchaser will be returned without interest
or offset, and this Subscription Agreement shall thereafter be of no further force or effect. If this subscription is rejected
in part, the funds for the rejected portion of this subscription will be returned without interest or offset, and this Subscription
Agreement will continue in full force and effect to the extent this subscription was accepted.

 

6.          Representations
and Warranties.

 

The Purchaser hereby acknowledges,
represents, warrants, and agrees as follows:

 

(a)          None
of the shares of Common Stock or the shares of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”)
offered pursuant to the Memorandum are registered under the Securities Act of 1933, as amended (the “Securities Act”),
or any state securities laws. The Purchaser understands that the offering and sale of the Units is intended to be exempt from registration
under the Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation D (“Regulation D”)
as promulgated by the United States Securities and Exchange Commission (the “SEC”) thereunder, based, in part, upon
the representations, warranties and agreements of the Purchaser contained in this Subscription Agreement;

 

    	-2-

    	 	 	 

    

 

(b)          Prior
to the execution of this Subscription Agreement, the Purchaser and the Purchaser's attorney, accountant, purchaser representative
and/or tax adviser, if any (collectively, the “Advisers”), have received the Memorandum and all other documents requested
by the Purchaser, have carefully reviewed them and understand the information contained therein;

 

(c)          Neither
the SEC nor any state securities commission or other regulatory authority has approved the Units, the Common Stock, the Warrants
or the Warrant Shares, or passed upon or endorsed the merits of the offering of Units or confirmed the accuracy or determined the
adequacy of the Memorandum. The Memorandum has not been reviewed by any federal, state or other regulatory authority;

 

(d)          All
documents, records, and books pertaining to the investment in the Units (including, without limitation, the Memorandum) have been
made available for inspection by such Purchaser and its Advisers, if any;

 

(e)          The
Purchaser and its Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or
persons acting on behalf of the Company concerning the offering of the Units and the business, financial condition and results
of operations of the Company, and all such questions have been answered to the full satisfaction of the Purchaser and its Advisers,
if any;

 

(f)          In
evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information
(oral or written) other than as stated in the Memorandum.

 

(g)          The
Purchaser is unaware of, is in no way relying on, and did not become aware of the Offering of the Units through or as a result
of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or
other communication published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including,
without limitation, internet “blogs,” bulletin boards, discussion groups and social networking sites) in connection
with the Offering and sale of the Units and is not subscribing for the Units and did not become aware of the Offering of the Units
through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by,
a person not previously known to the Purchaser in connection with investments in securities generally;

 

(h)          The
Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders' fees or the like
relating to this Subscription Agreement or the transactions contemplated hereby (other than commissions to be paid by the Company
to the Placement Agent or as otherwise described in the Memorandum);

 

(i)          The
Purchaser, together with its Advisers, if any, has such knowledge and experience in financial, tax, and business matters, and,
in particular, investments in securities, so as to enable it to utilize the information made available to it in connection with
the Offering to evaluate the merits and risks of an investment in the Units and the Company and to make an informed investment
decision with respect thereto;

 

    	-3-

    	 	 	 

    

 

(j)          The
Purchaser is not relying on the Company, the Placement Agent or any of their respective employees or agents with respect to the
legal, tax, economic and related considerations of an investment in the Units, and the Purchaser has relied on the advice of, or
has consulted with, only its own Advisers;

 

(k)          The
Purchaser is acquiring the Units solely for such Purchaser's own account for investment purposes only and not with a view to or
intent of resale or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal,
with any person to sell or transfer all or any part of the Units, the shares of Common Stock, the Warrants or the Warrant Shares,
and the Purchaser has no plans to enter into any such agreement or arrangement.

 

(l)          The
Purchaser must bear the substantial economic risks of the investment in the Units indefinitely because none of the securities included
in the Units may be sold, hypothecated or otherwise disposed of unless subsequently registered under the Securities Act and applicable
state securities laws or an exemption from such registration is available. Legends shall be placed on the securities included in
the Units to the effect that they have not been registered under the Securities Act or applicable state securities laws and appropriate
notations thereof will be made in the Company's stock books. Stop transfer instructions will be placed with the transfer agent
of the Units. The Company has agreed that purchasers of the Units will have, with respect to the shares of Common Stock and the
Warrant Shares, the registration rights described in the Registration Rights Agreement. Notwithstanding such registration rights,
there can be no assurance that an effective registration statement will be available, or that there will be a market, for resale
of the Units, the Common Stock, the Warrants or the Warrant Shares, nor can there be any assurance that such securities will be
freely transferable at any time in the foreseeable future.

 

(m)          The
Purchaser has adequate means of providing for such Purchaser's current financial needs and foreseeable contingencies and has no
need for liquidity from its investment in the Units for an indefinite period of time;

 

(n)          The
Purchaser is aware that an investment in the Units is high risk, involving a number of very significant risks and has carefully
read and considered the matters set forth under the caption “Risk Factors” in the Memorandum (including the documents
incorporated by reference therein), and, in particular, acknowledges that the Company has a limited operating history, significant
operating losses since inception, limited revenues to date, limited assets and is engaged in a highly competitive business;

 

(o)          The
Purchaser meets the requirements of at least one of the suitability standards for an “accredited investor” as that
term is defined in Regulation D and as set forth on the Accredited Investor Certification contained herein;

 

    	-4-

    	 	 	 

    

 

(p)          The
Purchaser (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to
execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions
hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association, joint stock
company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose
of acquiring the Units, such entity is duly organized, validly existing and in good standing under the laws of the state of its
organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of
state law or its charter or other organizational documents, such entity has full power and authority to execute and deliver this
Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof and
to purchase and hold the securities constituting the Units, the execution and delivery of this Subscription Agreement has been
duly authorized by all necessary action, this Subscription Agreement has been duly executed and delivered on behalf of such entity
and is a legal, valid and binding obligation of such entity; or (iii) if executing this Subscription Agreement in a representative
or fiduciary capacity, represents that it has full power and authority to execute and deliver this Subscription Agreement in such
capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company
or partnership, or other entity for whom the Purchaser is executing this Subscription Agreement, and such individual, partnership,
ward, trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform
pursuant to this Subscription Agreement and make an investment in the Company, and represents that this Subscription Agreement
constitutes a legal, valid and binding obligation of such entity. The execution and delivery of this Subscription Agreement will
not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to which the Purchaser is
a party or by which it is bound;

 

(q)          The
Purchaser and the Advisers, if any, have had the opportunity to obtain any additional information, to the extent the Company has
such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy
of the information contained in the Memorandum and all documents received or reviewed in connection with the purchase of the Units
and have had the opportunity to have representatives of the Company provide them with such additional information regarding the
terms and conditions of this particular investment and the financial condition, results of operations, business of the Company
deemed relevant by the Purchaser or the Advisers, if any, and all such requested information, to the extent the Company had such
information in its possession or could acquire it without unreasonable effort or expense, has been provided to the full satisfaction
of the Purchaser and the Advisers, if any;

 

(r)          Any
information which the Purchaser has heretofore furnished or is furnishing herewith to the Company or the Placement Agent is complete
and accurate and may be relied upon by the Company and the Placement Agent in determining the availability of an exemption from
registration under federal and state securities laws in connection with the offering of securities as described in the Memorandum.
The Purchaser further represents and warrants that it will notify and supply corrective information to the Company and the Placement
Agent immediately upon the occurrence of any change therein occurring prior to the Company's issuance of the securities contained
in the Units;

 

(s)          The
Purchaser has significant prior investment experience, including investment in non-listed and non-registered securities. The Purchaser
is knowledgeable about investment considerations in development-stage companies with limited operating histories. The Purchaser
has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The
Purchaser's overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s
net worth and financial circumstances and the purchase of the Units will not cause such commitment to become excessive. The investment
is a suitable one for the Purchaser;

 

    	-5-

    	 	 	 

    

 

(t)          The
Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which it or the Advisers,
if any, consider material to its decision to make this investment;

 

(u)          The
Purchaser acknowledges that any estimates or forward-looking statements or projections included in the Memorandum (including the
documents incorporated by reference therein) were prepared by the Company in good faith but that the attainment of any such projections,
estimates or forward-looking statements cannot be guaranteed by the Company and should not be relied upon;

 

(v)         No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or the Advisers, if
any, in connection with the Offering which are in any way inconsistent with the information contained in the Memorandum;

 

(w)          Within
five (5) days after receipt of a request from the Company or the Placement Agent, the Purchaser will provide such information and
deliver such documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company or the
Placement Agent is subject;

 

(x)          The
Purchaser's substantive relationship with the Placement Agent or subagent through which the Purchaser is subscribing for Units
predates the Placement Agent's or such subagent's contact with the Purchaser regarding an investment in the Units;

 

(y)          THE
SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND
ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES
ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT
AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN RECOMMENDED, APPROVED OR DISAPPROVED
BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE
FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM OR THIS
SUBSCRIPTION AGREEMENT. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL;

 

(z)          In
making an investment decision investors must rely on their own examination of the Company and the terms of the Offering, including
the merits and risks involved. The Purchaser should be aware that it will be required to bear the financial risks of this investment
for an indefinite period of time;

 

    	-6-

    	 	 	 

    

 

(aa)         (For
ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has been informed
of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan
assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification
of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision
to invest in the Company; (b) is independent of the Company or any of its affiliates; (c) is qualified to make such investment
decision; and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation
of the Company or any of its affiliates;

 

(bb)         The
Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at <http://www.treas.gov/ofac> before
making the following representations. The Purchaser represents that the amounts invested by it in the Company in the Offering
were not and are not directly or indirectly derived from activities that contravene federal, state or international laws and regulations,
including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among
other things, the engagement in transactions with, and the provision of services to, certain foreign countries, territories, entities
and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at
<http://www.treas.gov/ofac>. In addition, the programs administered by OFAC (the “OFAC Programs”) prohibit dealing
with individuals1 or entities in certain countries regardless
of whether such individuals or entities appear on the OFAC lists;

 

(cc)         To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser;
(3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for
whom the Purchaser is acting as agent or nominee in connection with this investment is a country, territory, individual or entity
named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the Company may not accept
any amounts from a prospective investor if such prospective investor cannot make the representation set forth in the preceding
paragraph. The Purchaser agrees to promptly notify the Company and the Placement Agent should the Purchaser become aware of any
change in the information set forth in these representations. The Purchaser understands and acknowledges that, by law, the Company
may be obligated to “freeze the account” of the Purchaser, either by prohibiting additional subscriptions from the
Purchaser, declining any redemption requests and/or segregating the assets in the account in compliance with governmental regulations,
and the Placement Agent may also be required to report such action and to disclose the Purchaser’s identity to OFAC. The
Purchaser further acknowledges that the Company may, by written notice to the Purchaser, suspend the redemption rights, if any,
of the Purchaser if the Company reasonably deems it necessary to do so to comply with anti-money laundering regulations applicable
to the Company and the Placement Agent or any of the Company’s other service providers. These individuals include specially
designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo programs;

 

 

1 These
individuals include specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC
sanctions and embargo programs.

 

    	-7-

    	 	 	 

    

 

(dd)         To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser;
(3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for
whom the Purchaser is acting as agent or nominee in connection with this investment is a senior foreign political figure,2
or any immediate family3 member or
close associate4 of a senior foreign political
figure, as such terms are defined in the footnotes below; and

 

(ee)         If
the Purchaser is affiliated with a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser receives deposits
from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents
and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country
in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related
to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank
to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not
have a physical presence in any country and that is not a regulated affiliate.

 

7.          Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company the Placement Agent (including its selected dealers, if any), and
their respective officers, directors, employees, agents, control persons and affiliates from and against all losses, liabilities,
claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating,
preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false
acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Purchaser
of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription
Agreement.

 

8.          Irrevocability;
Binding Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser,
except as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser
and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal
representatives, and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall
be joint and several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by
and be binding upon each such person and such person's heirs, executors, administrators, successors, legal representatives, and
permitted assigns.

 

 

 

2 A
“senior foreign political figure” is defined as a current or former senior official in the executive, legislative,
administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign
political party, or a senior executive of a foreign government-owned corporation. In addition, a “senior foreign political
figure” includes any corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign
political figure.

 

3 “Immediate
family” of a senior foreign political figure typically includes the figure’s parents, siblings, spouse, children and
in-laws.

 

4 A
“close associate” of a senior foreign political figure is a person who is widely and publicly known to maintain an
unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial
domestic and international financial transactions on behalf of the senior foreign political figure.

 

    	-8-

    	 	 	 

    

 

9.          Modification.
This Subscription Agreement shall not be modified or waived except by an instrument in writing signed by the party against whom
any such modification or waiver is sought.

 

10.         Immaterial
Modifications to the Registration Rights Agreement. The Company may, at any time prior to the First Closing, modify the Registration
Rights Agreement if necessary to clarify any provision therein, without first providing notice or obtaining prior consent of the
Subscriber, if, and only if, such modification is not material in any respect.

 

11.         Notices.
Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified
mail, return receipt requested, or delivered against receipt to the party to whom it is to be given (a) if to the Company, at the
address set forth above, or (b) if to the Purchaser, at the address set forth on the signature page hereof (or, in either case,
to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 11). Any notice
or other communication given by certified mail shall be deemed given at the time of certification thereof, except for a notice
changing a party's address which shall be deemed given at the time of receipt thereof.

 

12.         Assignability.
This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser
and the transfer or assignment of the shares of Common Stock or the Warrants shall be made only in accordance with all applicable
laws.

 

13.         Applicable
Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable
to contracts to be wholly-performed within said State.

 

14.         Arbitration.
The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that:

 

(a)          Arbitration
is final and binding on the parties.

 

(b)          The
parties are waiving their right to seek remedies in court, including the right to a jury trial.

 

(c)          Pre-arbitration
discovery is generally more limited and different from court proceedings.

 

(d)          The
arbitrator's award is not required to include factual findings or legal reasoning and any party's right to appeal or to seek modification
of rulings by arbitrators is strictly limited.

 

(e)          The
panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.

 

    	-9-

    	 	 	 

    

 

(f)          All
controversies which may arise between the parties concerning this Subscription Agreement shall be determined by arbitration pursuant
to the rules then pertaining to the Financial Industry Regulatory Authority, Inc. (“FINRA”) in New York City, New York.
Judgment on any award of any such arbitration may be entered in the Supreme Court of the State of New York or in any other court
having jurisdiction of the person or persons against whom such award is rendered. Any notice of such arbitration or for
the confirmation of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Agreement.
The parties agree that the determination of the arbitrators shall be binding and conclusive upon them.

 

15.         Blue
Sky Qualification. The purchase of Units under this Subscription Agreement is expressly conditioned upon the exemption from
qualification of the offer and sale of the Units from applicable federal and state securities laws. The Company shall not be required
to qualify this transaction under the securities laws of any jurisdiction and, should qualification be necessary, the Company shall
be released from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction.

 

16.         Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

17.         Confidentiality.
The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company, not otherwise
properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except
as may be required by law or for the performance of this Agreement, or use to the detriment of the Company or for the benefit of
any other person or persons, or misuse in any way, any confidential information of the Company, including any scientific, technical,
trade or business secrets of the Company and any scientific, technical, trade or business materials that are treated by the Company
as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging
to the Company and confidential information obtained by or given to the Company about or belonging to third parties.

 

18.         Miscellaneous.

 

(a)          This
Subscription Agreement, together with the Registration Rights Agreement, constitute the entire agreement between the Purchaser
and the Company with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings,
if any, relating to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent
for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or
provisions.

 

(b)          The
representations and warranties of the Company and the Purchaser made in this Subscription Agreement shall survive the execution
and delivery hereof and delivery of the shares of Common Stock and Warrants contained in the Units.

 

(c)          Each
of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the
transactions contemplated hereby are consummated.

 

    	-10-

    	 	 	 

    

 

(d)          This
Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original, but all of which
shall together constitute one and the same instrument.

 

(e)          Each
provision of this Subscription Agreement shall be considered separable and, if for any reason any provision or provisions hereof
are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or
affect the remaining portions of this Subscription Agreement.

 

(f)          Paragraph
titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement as set forth
in the text.

 

(g)          The
Purchaser understands and acknowledges that there may be multiple closings for this Offering.

 

19.         Omnibus
Signature Page. This Subscription Agreement is intended to be read and construed in conjunction with the Registration Rights
Agreement pertaining to the issuance by the Company of the shares of Common Stock and Warrants to subscribers pursuant to the Memorandum.
Accordingly, pursuant to the terms and conditions of this Subscription Agreement and such related agreements it is hereby agreed
that the execution by the Purchaser of this Subscription Agreement, in the place set forth herein, shall constitute agreement to
be bound by the terms and conditions hereof and the terms and conditions of the Registration Rights Agreement, with the same effect
as if each of such separate but related agreement were separately signed.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	-11-

    	 

    

 

Matinas
biopharma holdings, inc.

OMNIBUS SIGNATURE PAGE TO THE

SUBSCRIPTION AGREEMENT

AND REGISTRATION RIGHTS AGREEMENT

 

Subscriber
hereby elects to subscribe under the Subscription Agreement for a total of ______ Units at a price of $0.50 per Unit (NOTE: to
be completed by subscriber) and executes the Subscription Agreement and the Registration Rights Agreement. 

 

Date (NOTE: To be completed by subscriber):
__________________

 

If the Purchaser is an INDIVIDUAL, and if
purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:

 

	 	 	 
	Print Name(s)	 	Social Security Number(s)
	 	 	 
	 	 	 
	Signature(s) of Subscriber(s)	 	Signature
	 	 	 
	 	 	 
	Date	 	Address

 

If the Purchaser is a PARTNERSHIP, CORPORATION,
LIMITED LIABILITY COMPANY or TRUST:

 

	 	 	 
	Name of Partnership,	 	Federal Taxpayer
	Corporation, Limited	 	Identification Number
	Liability Company or Trust	 	 
	 	 	 
	By:	 	 	 
	 	Name:	 	State of Organization
	 	Title:	 	 
	 	 	 
	 	 	 
	Date	 	Address
	 	 	 
	Matinas BIOPHARMA HOLDINGS, 	 	 
	inc.	 	AEGIS CAPITAL CORP..
	 	 	 
	By:	 	 	By:	 
	 	Authorized Officer	 	 	Authorized Officer

 

    	14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]